Back to overview

3-year Industrial Postdoc Fellowship awarded to Lluís Riera-Ponsatí

This grant from the Innovation Fund Denmark (IFD) will help us in further establishing our drug discovery pipeline, aimed at developing disease-modifying RNA Therapies for Parkinson's Disease at NEUmiRNA, in collaboration with Aalborg University and the Center for RNA Medicine (CRM).
Funding
Publication
27.3.2026
Meet Neumirna at Conferences and Events in 2026
Find out where you can connect with our team this year
Read full article
Development
Publication
12.1.2026
Neumirna at AES: new data on NMT.001
At the American Epilepsy Society Annual Meeting, Neumirna presented two posters highlighting the potential of its RNA-based approach for drug-resistant epilepsy.
Read full article
Development
17.9.2025
Neumirna Therapeutics Appoints Ellen K. Donnelly as Chief Executive Officer
We are excited to announce that Ellen K. Donnelly, Ph.D. has been appointed Chief Executive Officer of Neumirna Therapeutics.
Read full article